At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 17 enrolled
Drug / intervention
PD-0332991drug
Likely dose
PD-0332991 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
In Brief
A Phase 1 clinical trial evaluating PD-0332991 for Lymphoma, Mantle-Cell. Completed, enrolled 17 participants across 6 sites.
Detailed Summary
This is a pilot study evaluating tumor activity using Positron Emission Tomography, which is also known as a "PET scan". This study will assess the safety of using PD-0332991 in patients with mantle cell lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Mantle-Cell
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2007
Enrollment StartMay 2007
Primary CompletionMar 2010
Study CompletionMar 2012
TodayJul 2026
First PostedJan 9, 2007
Enrollment StartMay 1, 2007
Primary CompletionMar 1, 2010
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.5 years ago
Interventions
PD-0332991drug
125 mg, oral, Days 1-21 of a 28-day cycle